Ann: September 2023 Quarterly Update and Appendix 4C, page-8

hmmm seems like all we really have going for us now is PTX-100. Omnicar seems to be shelved because a trial is too expensive to run. Sounds like they want to wait until they can find a partner to fund it or until the Biotech sector improves perhaps.

If the FDA don't approve this PTX-100 registration study, this stock is going to sit on the low cents for the foreseeable future. Even if they do approve it, a P2 will take 2-3 years so i have no high hopes for the share price increasing any time soon.

Not a very good short-term outlook unfortunately IMO.